Marcela Purtell, MD
Family Medicine · East Liverpool, OHNPI 1609892470
Payments from drug & device makers
Across 314 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$755
- AstraZeneca$706
- Pfizer$622
- Lilly USA, LLC$466
- AbbVie$435
- Boehringer Ingelheim$346
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,27299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $755 |
| AstraZeneca | 29 | $706 |
| Pfizer | 32 | $622 |
| Lilly USA, LLC | 32 | $466 |
| AbbVie | 24 | $435 |
| Boehringer Ingelheim | 25 | $346 |
| Johnson & Johnson | 18 | $193 |
| Amgen | 10 | $161 |
| GSK | 11 | $159 |
| Bayer | 8 | $137 |
| Amarin Pharma, Inc. | 3 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $130 |
| E.r. Squibb & Sons, L.L.C. | 6 | $103 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Astellas Pharma US Inc | 4 | $91 |
| Sumitomo Pharma America, Inc. | 5 | $90 |
| Corcept Therapeutics | 4 | $87 |
| Abbott | 4 | $79 |
| Shield Therapeutics Inc | 4 | $62 |
| Dexcom, Inc. | 3 | $61 |
| Merck | 4 | $57 |
| Novartis | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Lundbeck LLC | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Pulmonx Corporation | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,304 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 202 | $217,527 |
| OzempicSemaglutide | 132 | $171,764 |
| EliquisApixaban | 174 | $146,551 |
| RybelsusSemaglutide | 60 | $78,570 |
| MounjaroTirzepatide | 64 | $75,902 |
| XareltoRivaroxaban | 42 | $47,341 |
| FarxigaDapagliflozin Propanediol | 40 | $42,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $40,592 |
| TrulicityDulaglutide | 32 | $34,374 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $29,732 |
| JanuviaSitagliptin Phosphate | 23 | $25,071 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $20,974 |
| MyrbetriqMirabegron | 28 | $18,960 |
| ProliaDenosumab | 11 | $18,173 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $16,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $755 | $250,333192 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $346 | $225,800218 claims |
| PfizerEliquis | $622 | $146,551174 claims |
| Lilly USA, LLCMounjaro, Trulicity | $466 | $110,27596 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $159 | $70,58499 claims |
| Johnson & JohnsonXarelto, Invokamet | $193 | $55,93955 claims |
| AstraZenecaFarxiga | $706 | $42,81840 claims |
| MerckJanuvia | $57 | $25,07123 claims |
| AbbVieLinzess, Synthroid | $435 | $20,092119 claims |
| Astellas Pharma US IncMyrbetriq | $91 | $18,96028 claims |
| AmgenProlia | $161 | $18,17311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $10,03413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in East Liverpool
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.